FRACTYL HEALTH, INC.
Close on Oct 19, 2026
- Market cap
- $218.94M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | – | $-0.16 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 24, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | Before market open | – | – | – |
Press releases
Announcements Fractyl Health filed with the SEC
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
A clinician’s perspective: what REMAIN-1 means for patients and practice Adrian Dan, MD, FACS, FASMBS, DABS-MBS, DABOM Medical Director, Bariatric Surgery Texas Health in Flower Mound
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Positive One-Year Randomized REMAIN-1 Midpoint Cohort Results July 15, 2026 Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK. Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita ® for Post-GLP-1 Weight Maintenance
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita ® After GLP-1 Discontinuation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
January 29, 2026 Positive 6-Month Randomized Data from REMAIN-1 Midpoint Cohort - Accelerating Momentum Towards Revita’s Potential Approval and Launch Revita is for investigational use only in the United States. Revita has a CE mark in the EU/UK. Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
Results of operations · Other events · EX-99.1 to Form 8-K
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CALL NOTICE FOR ALL TRANCHE A COMMON STOCK PURCHASE WARRANTS (CUSIP 35168W129)
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita ® Procedure
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fractyl Health Reports Third Quarter 2025 Results; Revita ® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Announces Groundbreaking Data from REMAIN-1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Positive Randomized Data from REMAIN-1 Midpoint Cohort StudyRevita®: Unlocking Durable Weight Maintenance After GLP-1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita ® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fractyl Health Presents New Data at the American Diabetes Association’s 85 th Scientific Sessions Demonstrating its Rejuva ® Smart GLP-1 TM Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fractyl Health Advances Rejuva ® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Unveils New Rejuva ® Smart GLP-1 TM Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Reports Positive Early Data Showing Revita ® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Announces Increased Focus on Groundbreaking Revita ® Weight Maintenance and Rejuva ® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People wi th Obesity Who Discontinue GLP-1 Based Drugs
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Regulation FD disclosure · EX-99.1 to Form 8-K
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Fractyl Health Receives FDA IDE Approval for the Revita ®
Regulation FD disclosure · EX-99.1 to Form 8-K